476 related articles for article (PubMed ID: 29580864)
41. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.
Holman CJ; Karger AB; Mullan BD; Brundage RC; Balfour HH
Clin Transplant; 2012; 26(5):741-7. PubMed ID: 22385033
[TBL] [Abstract][Full Text] [Related]
42. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
[TBL] [Abstract][Full Text] [Related]
43. Epstein-Barr Virus Monitoring after an Allogeneic Hematopoietic Stem Cell Transplant: Review of the Recent Data and Current Practices in Canada.
Ratiu C; Dufresne SF; Thiant S; Roy J
Curr Oncol; 2024 May; 31(5):2780-2795. PubMed ID: 38785492
[TBL] [Abstract][Full Text] [Related]
44. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
[TBL] [Abstract][Full Text] [Related]
45. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
Ahmad I; Cau NV; Kwan J; Maaroufi Y; Meuleman N; Aoun M; Lewalle P; Martiat P; Crokaert F; Bron D
Transplantation; 2009 Apr; 87(8):1240-5. PubMed ID: 19384173
[TBL] [Abstract][Full Text] [Related]
46. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
[TBL] [Abstract][Full Text] [Related]
47. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
48. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
49. The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring.
Preiksaitis J; Allen U; Bollard CM; Dharnidharka VR; Dulek DE; Green M; Martinez OM; Metes DM; Michaels MG; Smets F; Chinnock RE; Comoli P; Danziger-Isakov L; Dipchand AI; Esquivel CO; Ferry JA; Gross TG; Hayashi RJ; Höcker B; L'Huillier AG; Marks SD; Mazariegos GV; Squires J; Swerdlow SH; Trappe RU; Visner G; Webber SA; Wilkinson JD; Maecker-Kolhoff B
Pediatr Transplant; 2024 Feb; 28(1):e14471. PubMed ID: 37294621
[TBL] [Abstract][Full Text] [Related]
50. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
[TBL] [Abstract][Full Text] [Related]
51. Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation.
Pagliuca S; Bommier C; Michonneau D; Meignin V; Salmona M; Robin M; Prata PH; Xhaard A; de Fontbrune FS; Feghoul L; Dhedin N; de Latour RP; Caillat-Zucman S; Goff JL; Socié G
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2490-2500. PubMed ID: 31421238
[TBL] [Abstract][Full Text] [Related]
52. Non-uniform
Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
Front Immunol; 2019; 10():2489. PubMed ID: 31736946
[TBL] [Abstract][Full Text] [Related]
53. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
54. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
[TBL] [Abstract][Full Text] [Related]
55. [Dynamic monitoring of plasma Epstein-Barr Virus DNA load can predict the occurrence of lymphoproliferative disorders after haploidentical hematopoietic stem cell transplantation].
Chen J; Sun YQ; Xu LP; Zhang XH; Liu KY; Mo XD; Cheng YF; Huang XJ; Wang Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):284-288. PubMed ID: 37356996
[No Abstract] [Full Text] [Related]
56. Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus.
Han SB; Bae EY; Lee JW; Jang PS; Lee DG; Chung NG; Jeong DC; Cho B; Lee SJ; Kang JH; Kim HK
Int J Hematol; 2014 Aug; 100(2):188-99. PubMed ID: 24981711
[TBL] [Abstract][Full Text] [Related]
57. Epstein-Barr virus infection in adult renal transplant recipients.
Morton M; Coupes B; Roberts SA; Johnson SL; Klapper PE; Vallely PJ; Picton ML
Am J Transplant; 2014 Jul; 14(7):1619-29. PubMed ID: 24815922
[TBL] [Abstract][Full Text] [Related]
58. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
Naik S; Riches M; Hari P; Kim S; Chen M; Bachier C; Shaughnessy P; Hill J; Ljungman P; Battiwalla M; Chhabra S; Daly A; Storek J; Ustun C; Diaz MA; Cerny J; Beitinjaneh A; Yared J; Brown V; Page K; Dahi PB; Ganguly S; Seo S; Chao N; Freytes CO; Saad A; Savani BN; Woo Ahn K; Boeckh M; Heslop HE; Lazarus HM; Auletta JJ; Kamble RT
Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099
[TBL] [Abstract][Full Text] [Related]
59. Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.
Barlev A; Zimmermann H; Guzman-Becerra N; Mehta A; Xing B; Macabeo B; Thivolet M; Brookhart MA
J Med Econ; 2024; 27(1):789-795. PubMed ID: 38727527
[TBL] [Abstract][Full Text] [Related]
60. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.
Stevens SJ; Verschuuren EA; Pronk I; van Der Bij W; Harmsen MC; The TH; Meijer CJ; van Den Brule AJ; Middeldorp JM
Blood; 2001 Mar; 97(5):1165-71. PubMed ID: 11222357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
